A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants With Persistent Obesity or Overweight Treated With a Weekly Incretin, With and Without Type 2 Diabetes
Eli Lilly and Company
900 participants
Feb 10, 2026
INTERVENTIONAL
Conditions
Summary
The main purpose of this study is to evaluate the efficacy and safety of eloralintide compared with placebo in participants with persistent obesity or overweight, with or without type 2 diabetes, and on stable incretin background therapy. Participation in the study will last about 80 weeks.
Eligibility
Inclusion Criteria10
- Are on stable incretin therapy at screening
- With persistent obesity or overweight defined as:
- ≥30 kg/m2 OR
- ≥27 kg/m2 with at least one existing obesity related complication at screening:
- hypertension
- dyslipidemia
- obstructive sleep apnea
- cardiovascular disease (for example, ischemic cardiovascular disease, New York Heart Association Functional Class I-III heart failure), or
- type 2 diabetes
- Have a stable body weight (\<5% body weight change) at screening
Exclusion Criteria14
- Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed \>1 year before screening)
- Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening)
- Have type 1 diabetes
- Have taken any of the following antihyperglycemic medications within 90 days before screening:
- dipeptidyl peptidase-4 (DPP-4) inhibitors
- amylin analogs
- insulin
- Have had within 90 days prior to screening:
- heart attack
- stroke
- coronary artery revascularization
- unstable angina, or
- hospitalization due to congestive heart failure
- Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure
Interventions
Administered SC
Administered SC
Locations(178)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07392190